Key result
Lipoprotein lipase dysregulation in diabetes drives cardiac lipotoxicity and promotes diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
This review provides an overview of cardiac lipoprotein lipase (LPL), its role in delivering fatty acids to the heart for ATP generation, and its regulation in physiological and pathological states.
Ninety percent of plasma fatty acids (FAs) are contained within lipoprotein-triglyceride, and lipoprotein lipase (LPL) is robustly expressed in the heart. Hence, LPL-mediated lipolysis of lipoproteins is suggested to be a key source of FAs for cardiac use. Lipoprotein clearance by LPL occurs at the apical surface of the endothelial cell lining of the coronary lumen. In the heart, the majority of LPL is produced in cardiomyocytes and subsequently is translocated to the apical luminal surface. Here, vascular LPL hydrolyzes lipoprotein-triglyceride to provide the heart with FAs for ATP generation. This article presents an overview of cardiac LPL, explains how the enzyme works, describes key molecules that regulate its activity and outlines how changes in LPL are brought about by physiological and pathological states such as fasting and diabetes, respectively.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2021) conducted a review in Diabetic cardiomyopathy and cardiac metabolism. Lipoprotein lipase (LPL) metabolism was evaluated. Lipoprotein lipase mediates the delivery of fatty acids to the heart for energy, and its dysregulation during diabetes shifts cardiac metabolism toward lipotoxicity, contributing to diabetic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: